DocGo Inc. Common Stock reported strong Q4 2025 results, with revenue guidance raised for 2026. Explore key financial metrics and strategic initiatives.
Symbol:
DocGo Inc. Common Stock Q4 2025 Earnings Call Analysis
DocGo Inc. Common Stock reported a strong finish to 2025, showcasing resilience amid operational challenges. The company's revenue for the fourth quarter reached $74.9 million, surpassing expectations, while the adjusted EBITDA loss was $11.6 million. With increased guidance for 2026, DocGo's management has positioned the company for growth through strategic initiatives and operational improvements, signaling positive momentum for investors.
Financial Performance
In Q4 2025, DocGo achieved a revenue of $74.9 million, a notable decline from $120 million in Q4 2024. However, this decline was primarily attributed to the winding down of migrant-related projects. Excluding these revenues, the company reported an 11% year-over-year increase in revenue during the fourth quarter, indicating strong underlying growth in its core operations.
For the full year, total revenue amounted to $322.2 million, down from $616.6 million in 2024. In the medical transportation segment, revenue increased to $50.2 million in Q4, up from $49.1 million in the same quarter of the previous year. Conversely, mobile health revenue decreased to $24.8 million, primarily due to the wind down of migrant revenues, which had accounted for about $7.4 million in previous periods.
DocGo's adjusted EBITDA loss for the fourth quarter was $11.3 million, compared to a gain of $1.1 million in Q4 2024. For the entire year, the adjusted EBITDA loss totaled $28.6 million, a significant reduction from the $60 million loss reported in 2024. The adjusted gross margin for Q4 was 32.5%, slightly down from 33.5% in Q4 2024, with medical transportation gross margins showing improvements at 32.8%.
Strategic Initiatives
One of the key drivers of DocGo's optimistic outlook is the integration of SteadyMD, which the company acquired in late 2025. SteadyMD generated $6.1 million in revenue during its initial months within DocGo, and its contribution is expected to grow significantly in 2026. With over 4 million patient interactions in 2025, SteadyMD is positioned to enhance DocGo's telehealth services, supporting the company's goal of expanding its virtual care offerings.
The company has also made strides in improving hiring rates, particularly in the medical transportation segment. DocGo filled 206 EMT and paramedic roles out of 546 open positions, leading to a reduction in reliance on outsourced rides. This hiring success is expected to enhance margins as overtime rates decline from historical highs, contributing to overall operational efficiency.
DocGo's continued expansion of care gap closure programs with major insurance payers is another strategic initiative. The company is set to launch preventative exams in Kentucky, expanding its reach into new markets. These initiatives, combined with the introduction of AI and automation in administrative functions, demonstrate DocGo's commitment to leveraging technology for operational efficiencies and improved service delivery.
Future Outlook
Looking ahead, DocGo has updated its revenue guidance for 2026 to a range of $290 million to $310 million, up from the previous estimate of $280 million to $300 million. This growth projection represents a 15% to 23% increase over 2025's revenues, reflecting confidence in the company's expanding customer base and service offerings.
Management expects an adjusted EBITDA loss of $5 million to $10 million for 2026, a substantial improvement from prior expectations of a $15 million to $25 million loss. The company anticipates achieving profitability in the second half of 2026, driven by enhanced revenue growth and cost-cutting measures through its Efficiency Innovation portfolio, which is expected to yield $5 million to $6 million in savings in 2026.
Despite facing short-term cash flow pressures, primarily due to operational losses and working capital requirements, DocGo's management is actively working on reducing cash utilization and improving financial flexibility. The company is exploring strategic alternatives to maximize shareholder value, indicating a proactive approach to addressing financial challenges.
Conclusion
In summary, DocGo Inc. Common Stock has demonstrated resilience and a strong operational foundation despite challenges in 2025. With promising revenue guidance for 2026 and strategic initiatives to enhance efficiency and service delivery, the company is well-positioned for growth. Investors should monitor DocGo's progress in executing its strategic plans, particularly as it integrates SteadyMD and expands its service offerings. The anticipated improvement in profitability and operational efficiency may provide a positive outlook for shareholders in the coming year.